Argenx Sets New Records: In-Depth Review

? On August 26, 2025, shares of the Dutch biotechnology company Argenx (ARGX) surged to an all-time high following the release of its quarterly report.

Key report highlights:

• Earnings per share (EPS): +664%, reaching $3.74 — reflecting significant improvement in operational efficiency and successful product commercialization.
• Revenue: +98%, totaling $967.2 million, reflecting growing demand for the company’s key product and expanded market share.
• Composite Rating: 96/99 — Argenx is in the elite club of stocks, ranking in the top 4% of all global equities, making it attractive for both institutional and retail investors.

Company Overview:

• Headquarters: Ghent, Belgium
• Products: main product — Vyvgart (efgartigimod alfa-FcAb)
• Market capitalization: approximately $42.5 billion
• Exchanges: NASDAQ (USA) and Euronext (Belgium)
• Financial performance: Q2 2025 revenue up 98% to $967.2 million, EPS +664% to $3.74

Product Portfolio and Growth Drivers
The company’s commercial success is primarily driven by Vyvgart, a treatment for the rare autoimmune disease CIDP (Chronic Inflammatory Demyelinating Polyneuropathy).

This specialized drug generates a significant portion of revenue and supports the company’s financial stability.

Technical Analysis and Trading Potential
Technically, Argenx shares broke the resistance base and are trading just 3% above the key entry point of $678.21, still making them attractive for purchase.

Recommendations for Traders and Investors:

• Entry: $678–690 — the current range where the stock looks promising for purchase.
• Stop-loss: $650 — protection of capital against potential short-term corrections.
• Target: $750–770, expected growth +10–12%, reflecting the potential strengthening of the position in the coming weeks.

Sector Risks and Considerations:
Despite impressive performance, several risk factors should be considered:

• Dependence on a single key drug: Vyvgart generates the majority of the company’s revenue, making financial results vulnerable to regulatory changes, competition, and market dynamics.
• High volatility in the biotech sector: stocks in this segment are subject to sharp price swings, requiring careful position management.

⚠️ Conclusion:
Argenx demonstrates impressive growth and strengthens its position in the top 4% of the global equity market according to the Composite rating. Strong revenue and EPS figures, successful commercialization of Vyvgart, and technical attractiveness make the stock an appealing option for medium-term investment. Investors should consider key risks and follow capital management strategies to fully leverage growth potential.